 Company Information |
Listed in:
Pharmaceutical & Medicine Manufacturing
Description:
QLT Inc. is a global biopharmaceutical company dedicated to the
discovery, development and commercialization of innovative
therapies to treat cancer, eye diseases and immune disorders.
Combining expertise in ophthalmology, oncology and photodynamic
therapy, QLT has commercialized two products to date, including
Visudyne therapy which is the most successfully launched
ophthalmology product ever.
ESTABLISHED
Formed in 1981. Became a public company in 1986.
FOUNDERS
Founded by a group of University of British Columbia professors,
including Dr. Julia Levy who served as the Company's President
and CEO from 1995 to 2002.
EMPLOYEES
Over 350 professionals in the fields of science, research,
business and technology.
COMMERCIAL PRODUCTS
Visudyne (verteporfin) for the treatment of wet age-related
macular degeneration (AMD), pathologic myopia and presumed
ocular histoplasmosis. To date, Visudyne therapy is approved in
over 60 countries. For more information, go to our commercial
center.
Photofrin, the world's first approved photodynamic therapy drug
used in the treatment of various cancers. Before selling the
rights to Photofrin to Axcan Pharma Inc. on June 8, 2000, QLT
received a number of worldwide approvals for Photofrin for
various cancerous conditions.
PARTNERSHIPS / ALLIANCES
QLT has an exclusive worldwide co-development agreement with
Novartis Ophthalmics, the eye health unit of Novartis AG. QLT
manufacturers Visudyne, while Novartis Ophthalmics markets and
distributes the product worldwide.
QLT and Novartis Ophthalmics collaborate with Lumenis Ltd. and
Carl Zeiss for the supply of lasers used in conjunction with
Visudyne therapy.
|
| Map |
|
|
| Products |
 |
Biotechnology And Pharmaceutical Products
|
|
|
 |
|